Arbutus Biopharma (ABUS) Set to Announce Quarterly Earnings on Monday

Arbutus Biopharma (NASDAQ:ABUS) is set to announce its earnings results after the market closes on Monday, March 19th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.

Shares of Arbutus Biopharma (NASDAQ ABUS) opened at $5.80 on Monday. The firm has a market capitalization of $319.30, a P/E ratio of -1.16 and a beta of 1.02. The company has a debt-to-equity ratio of 0.08, a current ratio of 11.03 and a quick ratio of 11.03. Arbutus Biopharma has a 52-week low of $2.55 and a 52-week high of $8.25.

How to Become a New Pot Stock Millionaire

An institutional investor recently raised its position in Arbutus Biopharma stock. Vanguard Group Inc. lifted its stake in Arbutus Biopharma Corp (NASDAQ:ABUS) by 2.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 77,413 shares of the biopharmaceutical company’s stock after buying an additional 2,035 shares during the period. Vanguard Group Inc. owned about 0.14% of Arbutus Biopharma worth $279,000 at the end of the most recent reporting period. 62.14% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have weighed in on ABUS shares. BidaskClub downgraded Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, December 2nd. ValuEngine downgraded Arbutus Biopharma from a “sell” rating to a “strong sell” rating in a research report on Friday, December 15th. Zacks Investment Research downgraded Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. B. Riley started coverage on Arbutus Biopharma in a research report on Friday, January 5th. They issued a “buy” rating and a $10.00 target price for the company. Finally, Chardan Capital reiterated a “buy” rating on shares of Arbutus Biopharma in a research report on Tuesday, January 16th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $12.50.

ILLEGAL ACTIVITY NOTICE: “Arbutus Biopharma (ABUS) Set to Announce Quarterly Earnings on Monday” was first published by Markets Daily and is owned by of Markets Daily. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.themarketsdaily.com/2018/03/12/arbutus-biopharma-abus-set-to-announce-quarterly-earnings-on-monday.html.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Earnings History for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply